×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Cell: Substantia Nigra Neurons in Progressive Supranuclear Palsy
cell
1,959 words
KG: PSP
2026-03-24
kind:cell-type
section:cell-types
state:published
Contents
Substantia Nigra Neurons in Progressive Supranuclear Palsy
🧫
Cell Type Info
Cell Type
PSP
Key Pathways
Differentiation
Associated Diseases
ALS
,
Aging
,
Als
,
Alzheimer
,
Dementia
,
Frontotemporal Dementia
Related Genes
ALZHEIMER'S DISEASE
,
SV2A
Linked Hypotheses
38 hypotheses
Knowledge Graph
Related Hypotheses (15)
Heterogeneous astrocyte activation states differentially imp
Score: 0.52
Astrocyte-Mediated Microglial Memory Erasure
Score: 0.46
APOE-Dependent Autophagy Restoration
Score: 0.61
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming
Score: 0.61
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S
Score: 0.60
Microbial Inflammasome Priming Prevention
Score: 0.58
Synthetic Biology BBB Endothelial Cell Reprogramming
Score: 0.57
Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.55
Senescent Cell Mitochondrial DNA Release
Score: 0.54
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.52
Dual-Circuit Tau Vulnerability Cascade
Score: 0.50
Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio
Score: 0.49
Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioener
Score: 0.41
Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem
Score: 0.38
Age-Dependent Complement C4b Upregulation Drives Synaptic Vu
Score: 0.47
Show 10 more
Related Analyses (11)
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Mitochondrial transfer between neurons and glia
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · completed
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · completed
Show 6 more
Related Experiments (28)
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
iPSC-NPC effects on astrocytes in vitro ICH model
exploratory · proposed · Score: 0.90
Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90
RBG treatment in ApoE-/- atherosclerosis mouse model
validation · proposed · Score: 0.90
Leukocyte gene expression analysis in COVID-19 patients
exploratory · proposed · Score: 0.90
Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80
NLRP3 Inflammasome Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Show 23 more
Knowledge Graph (12 edges)
PSP
downregulates
SV2A
PSP
associated_with
SP1
PSP
associated_with
APOE
PSP
associated_with
TAU
PSP
associated_with
KIF13A
PSP
associated_with
TRIM24
PSP
associated_with
STX6
PSP
associated_with
MAPT
PSP
activates
VPS29
PSP
activates
MAPT